TP53 mutation and other critical gene mutations have been shown to alter multiple cancer related pathways in bladder cancer and thus promote disease progression, which makes it a potential therapeutic target (Bakkar et al., 2003; Choi et al., 2014; Gui et al., 2011; Liu & Kwiatkowski, 2015). Here, TP53 is linked to urinary bladder carcinoma.